Quest Integrity v. Cokebusters Puts Cloud-Based Medical Diagnostic Patents at Risk of On-Sale Bar

Medtech companies offering cloud-based services should carefully examine their technologies for potential patentable inventions prior to offering services to others.

4 Min Read
Quest Integrity v. Cokebusters Puts Cloud-Based Medical Diagnostic Patents at Risk of On-Sale Bar
Image by Arek Socha from Pixabay 

A growing trend in medicine is the use of cloud-based services to analyze patient data and assist with diagnosis and/or treatment. Such services may utilize machine learning and other algorithms that are processed on servers owned and controlled by the service provider. The service provider never sells the hardware responsible for running the diagnostic algorithms, nor does it publicly disclose the algorithms or hardware used. The service provider might thus believe that it can offer its service while preserving the patentability of its non-public system and components thereof. But the Federal Circuit’s recent decision in Quest Integrity USA LLC v. Cokebusters USA Inc. suggests otherwise.1

In Quest, the patent at issue claimed a system for assisting with the inspections of commercial furnaces.2 The system received data from sensors placed throughout the furnace, stored the data, algorithmically analyzed the data, and generated a two- or three-dimensional image of the furnace for visual inspection and diagnosis.3 The application for the patent was filed in June 2004.4

Quest (the patentee) had used this patented system commercially on at least one occasion more than one year prior to filing its patent application, in February-March 2003.5 It inspected the furnace of a customer for $72,060, providing the customer with two inspection reports.6 Quest did not sell any hardware or software to the customer during this exchange.7 Nor did it disclose the algorithm or hardware comprising the system.

Quest later sued Cokebuster, a competitor, for infringing the patent. Cokebuster argued that the patent was invalid under the 35 U.S.C. § 102(b) on-sale bar provision (pre-AIA), which states that a patent is invalid if “the invention was . . . on sale in this country, more than one year prior to the date of the application for patent in the United States.”8 According to Cokebuster, Quest sold the invention in 2003 when it provided a customer with inspection reports for profit.9 The Federal Circuit agreed with Cokebuster, stating that “[s]ale of a product (here, sale of the [inspection r]eports) produced by performing a claimed process implicates the on-sale bar.”10 The court found it irrelevant that Quest did not sell the furnace inspection hardware or software.11 The court therefore found the claims invalid.12

In view of Quest, those in the cloud-based diagnostic services industry should be cautious about offering services (e.g., testing or diagnostic reports) prior to filing applications for all desired patent protection. Offering a cloud-based service for profit might be considered a commercial sale of the system as a whole, even if the customer has no knowledge of how the system works and is given no control over the system’s operation. It is not clear from Quest whether individual hardware components of the system (e.g., a specialty processor or drive) are deemed on sale for purposes of 35 U.S.C. § 102(b) when the system as a whole is used to serve a customer, but one could argue based on Quest that at least every necessary component of the system is on sale under such circumstances.

Cloud-based service providers should be particularly careful now, as the one-year grace period for the on-sale bar discussed in Questis not available for newly-filed patent applications.13 This means that in most cases, the sale of a cloud-based service might immediately serve as anticipatory prior art and potentially render invalid future patent applications on the underlying technology.

Cloud-based service providers should thus carefully examine their technology for potential patentable inventions prior to offering services to others. For example, even where a current service might be of minimal commercial value, the technology underlying that service might have future applications with vastly greater value. Service providers do not want to find themselves in the position where they cannot patent an important technology because they offered a downstream service for sale before they recognized the technology’s potential.

However, even when a service provider has unwittingly offered a valuable unpatented technology for sale as in Quest, all is not necessarily lost. The technology would still qualify for trade secret protection provided the service provider did not disclose the underlying technology. This would not prevent competitors from independently developing the technology, but it would prevent competitors from misappropriating it. Note, however, that filing a patent application results in the public disclosure of the underlying technology, thereby eliminating the potential for trade secret protection. So if a service provider opts for trade secret protection, it must do so prior to filing for patent protection. Quest, for example, found itself in the unenviable position of publicly disclosing its technology by filing a patent application and then having its patent invalidated under the on-sale bar, leaving Quest with neither patent or trade secret protection over its invention. Cloud-based service providers should take care not to repeat Quest’s missteps.


  1. 924 F.3d 1220 (Fed. Cir. 2019).

  2. Id. at 1223-25.

  3. Id.

  4. Id. at 1227.

  5. Id. at 1225.

  6. Id.

  7. Id.

  8. 35 U.S.C. § 102(b) (pre-AIA).

  9. Quest, 924 F. 3d at 1225.

  10. Id. at 1227.

  11. Id.

  12. Id. at 1235. For certain claims (claims 30 and 40), the Federal Circuit remanded for further proceedings regarding whether Quest practiced these claims when providing its services in 2003.

  13. Compare 35 U.S.C. § 102(b) (pre-AIA) with 35 U.S.C. § 102(a)-(b) (post-AIA).

About the Author(s)

Matthew Murphy

Matthew Murphy is an attorney with Axinn. He has experience in intellectual property and complex litigation across the medical device, pharmaceutical, life sciences, and consumer-driven healthcare industries. He has represented clients in a number of legal matters, including patent litigation, sham litigation proceedings, contract actions, and more. He has worked on the development of novel remedies arguments to defend multiple multi-million dollar claims.

David Ludwig

David Ludwig is an attorney with Axinn. His practice focuses on patent litigation in the pharmaceutical, mechanical, and optical arts industries, with emphasis on pharmaceutical cases brought under the Hatch-Waxman Act. His litigation experience includes patent cases involving medical devices, scientific instruments, and food and drug law. David has represented a number of clients in several USPTO inter partes review and interference proceedings.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like